| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Sweet taste receptors (TAS1R2/TAS1R3); metabolic pathways related to glucose and lipid metabolism.
|
|---|---|
| ln Vitro |
11-Deoxymogroside V exhibits sweet-tasting properties similar to mogroside V but with potentially different pharmacokinetic and metabolic profiles due to the absence of the C-11 hydroxyl group. As a cucurbitane-type triterpenoid glycoside, it may have antioxidant, anti-inflammatory, and metabolic regulatory activities. The compound is primarily used as an analytical standard for the identification and quantification of mogroside derivatives in Luo Han Guo extracts and related products.
|
| ln Vivo |
In vivo studies of 11-deoxymogroside V are limited. As a derivative of mogroside V, it is expected to have similar metabolic effects, including potential regulation of glucose metabolism and insulin sensitivity. Mogrosides are known to be metabolized by intestinal microbiota to release aglycones that are absorbed systemically. Further studies are needed to characterize the specific in vivo activities of this deoxy derivative.
|
| Enzyme Assay |
Non-cell-based assays for 11-deoxymogroside V are typically analytical in nature. HPLC-UV, HPLC-ELSD, or LC-MS/MS methods are used for identification and quantification of the compound in plant extracts and finished products. Standard analytical protocols involve separation on C18 reverse-phase columns with gradient elution using water-acetonitrile mobile phases. The compound serves as a reference standard for method validation and quality control.
|
| Cell Assay |
Cell-based studies for 11-deoxymogroside V are limited. Based on related mogrosides, potential assays include: glucose uptake assays in adipocytes or muscle cells; anti-inflammatory assays in macrophage cell lines measuring cytokine production; and antioxidant assays measuring ROS reduction. The compound may be tested in intestinal epithelial cells to study its metabolism and transport.
|
| Animal Protocol |
In vivo animal studies for 11-deoxymogroside V are not well documented. Related mogrosides have been studied in rodent models of diabetes and obesity, where they demonstrated glucose-lowering and lipid-regulating effects. Typical protocols involve oral administration of the compound to mice or rats, followed by measurement of blood glucose, insulin, lipid profiles, and tissue analysis. Pharmacokinetic studies assess absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data specific to 11-deoxymogroside V are limited. Mogroside V and related compounds are known to have poor oral bioavailability due to their large molecular size and glycosidic nature. They are metabolized by intestinal microbiota to smaller aglycones that are absorbed. The deoxy derivative may have altered pharmacokinetic properties compared to mogroside V. The compound is stable under recommended storage conditions and is soluble in aqueous and organic solvents.
|
| Toxicity/Toxicokinetics |
Toxicological data for 11-deoxymogroside V are limited. Mogrosides are generally recognized as safe for use as sweeteners and have a long history of consumption as part of Luo Han Guo extract. No significant toxicity has been reported for mogroside derivatives. Standard laboratory safety practices should be followed when handling this compound. It is intended for research and analytical use only.
|
| References | |
| Additional Infomation |
11-Deoxymogroside V is a cucurbitane-type triterpenoid glycoside and a deoxy derivative of mogroside V, the primary sweet-tasting compound in Siraitia grosvenorii (Luo Han Guo). It is used as a reference standard for quality control of Luo Han Guo extracts and related products. The compound is of interest for its potential sweetening properties and as a tool for studying the structure-activity relationships of mogroside derivatives. It is for research use only.
|
| Molecular Formula |
C60H102O28
|
|---|---|
| Molecular Weight |
1271.44
|
| Exact Mass |
1270.655
|
| CAS # |
1707161-17-8
|
| PubChem CID |
102236129
|
| Appearance |
White to off-white solid
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.637
|
| LogP |
0.93
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
28
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
88
|
| Complexity |
2320
|
| Defined Atom Stereocenter Count |
34
|
| SMILES |
CC(CCC(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O)C(C)(C)O)C1CCC2(C)C3CC=C4C(CCC(OC5OC(COC6OC(CO)C(O)C(O)C6O)C(O)C(O)C5O)C4(C)C)C3(C)CCC12C |c:53|
|
| InChi Key |
FXMONPOKYCDPKD-PKCSIHSOSA-N
|
| InChi Code |
InChI=1S/C60H102O28/c1-24(9-13-35(57(4,5)78)87-55-50(88-54-49(77)43(71)38(66)30(21-63)83-54)45(73)40(68)32(85-55)23-80-52-47(75)42(70)37(65)29(20-62)82-52)25-15-16-60(8)33-12-10-26-27(58(33,6)17-18-59(25,60)7)11-14-34(56(26,2)3)86-53-48(76)44(72)39(67)31(84-53)22-79-51-46(74)41(69)36(64)28(19-61)81-51/h10,24-25,27-55,61-78H,9,11-23H2,1-8H3/t24-,25-,27-,28-,29-,30-,31-,32-,33+,34+,35-,36-,37-,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,49-,50-,51-,52-,53+,54+,55+,58+,59-,60+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[[(3S,8S,9R,10S,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
11-Deoxymogroside V
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7865 mL | 3.9325 mL | 7.8651 mL | |
| 5 mM | 0.1573 mL | 0.7865 mL | 1.5730 mL | |
| 10 mM | 0.0787 mL | 0.3933 mL | 0.7865 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
